New generation skin sensitisation testing technologies explained


Tuesday 15th September

3.00 – 3.30pm BST

In vitro skin sensitisation testing has come a long way in recent years, with the adoption of genomic technology proving to be a particularly exciting development with great potential.

GARD® tests combine genomic data from a relevant human cell type with machine learning to create a prediction model for identification of chemical sensitisers. This holistic, information-rich approach provides prediction accuracy exceeding 90%.

XCellR8 have partnered with SenzaGen to bring you this half hour webinar to explain more about how these methods work, from determining potency to animal-product-free solutions.

You will learn:

  • How GARD assays can be used for the safety assessment of chemicals, formulations and finished products
  • How the new animal-product-free version of GARD®skin can help support vegan tested claims
  • How GARD is meeting the challenges of skin sensitisation potency and dose-response

Who should attend?

This webinar is designed for anyone involved in cosmetic product development, including formulators, regulatory managers, safety assessors and toxicologists. You don’t need a technical background on genomics, machine learning or programming.

Register today